ArticleThe oncologist2026
Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype for which neoadjuvant chemotherapy (NACT) is used for locally advanced (LA) disease. Patients with TNBC who experienced a pathologic complete response (pCR) following NACT have been found to have extended overall survival (OS) compared to patients with residual disease. Sparse data exist on the frequency and impact of pCR following NACT for TNBC in East Africa.
methodsWe retrospectively reviewed patients diagnosed with LA TNBC who received NACT between 2018 and 2022 at Moi Teaching and Referral Hospital in Eldoret, Kenya. After NACT, patients underwent mastectomy in which specimens were reviewed histologically as either pCR or residual disease in the breast and/or axilla. Clinical data were analyzed using descriptive statistics and Kaplan-Meier methods.
resultsSixty-nine women with LA TNBC were included. Patient characteristics at diagnosis: Median age = 51 years (IQR 44-60); T4 disease = 34 (49%); and nodal involvement = 62 (91%). Forty-six patients (67%) received anthracycline/taxane-based chemotherapy with a median of 8 cycles (IQR 6-8), and 47 (68%) underwent mastectomy, with only 7% achieving pCR. Assuming all lost to follow-up died, the worst-case OS was 83% and 56% at 1 and 2 years, respectively.
conclusionsIn this LMIC setting, patients who presented with LA TNBC had lower pCR rates following NACT than observed in high-income countries. Our findings highlight the critical need for innovative, cost-effective programs focused on early detection of breast cancer, linkage of care, and delivery of more effective therapies to improve outcomes in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.